Compare McKesson Corporation (MCK) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Tyson Foods, Inc. — how do they compare? McKesson Corporation trades at $824.96 (market cap $97.35B), while Tyson Foods, Inc. trades at $57.12 (market cap $20.42B). The key difference: McKesson Corporation is far larger — about 4.8× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| MCK | TSN | |
|---|---|---|
Market Cap | $97.35B | $20.42B |
Sector | Health | Consumer Staples |
52-Week High | $995.69 | $68.75 |
52-Week Low | $659.01 | $50.72 |
Enterprise Value | $101.98B | $28.01B |
Dividend Yield | 0.39% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Tyson Foods (TSN) trades at $58.245, up 0.82% today, with a bearish technical signal but mixed earnings history. The company reported Q1 2026 EPS of $0.87, beating estimates, but faces margin pressures with a net income margin of 0.81%. Recent news highlights strategic product launches and executive appointments, while cash flow trends show operational strength but negative net cash flow in 2025.
Outlook is cautiously optimistic with a consensus price target of $68.80, implying 18% upside, supported by 50% analyst buy ratings. Risks include volatile protein markets and debt levels, but long-term growth in prepared foods and dividend stability offer value. Investors should weigh near-term margin challenges against strategic initiatives and analyst confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
